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Abstract
Members of the Cryptococcus species complex (C. neoformans and
C. gattii) are opportunistic pathogens responsible for frequently
fatal cases of meningoencephalitis. These yeasts have been classiﬁed
into ﬁve serotypes. Serotypes A andD are assigned to C. neoformans
var. grubii and C. neoformans var. neoformans, respectively, Serotype
AD strains are hybrids and serotype B and C strains are considered
to belong to the related but distinct species C. gattii. Previous stud-
ies have identiﬁed ‘serotype-associated’ alleles of several genes in
the Cryptococcus species complex. We developed a loop-mediated
isothermal DNA ampliﬁcation method using CAP59 allele-speciﬁc
primers to identify the serotypes A, D and B/C of the Cryptococcus
species complex.
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The Cryptococcus species complex contains the two species,
Cryptococcus neoformans and Cryptococcus gattii. Cryptococcus
neoformans is a medically important yeast responsible for fre-
quently fatal cases of meningoencephalitis, mainly in immuno-
compromised hosts [1]. Traditionally, C. neoformans has been
classiﬁed into three serotypes, i.e. A (C. neoformans var. gru-
bii), D (C. neoformans var. neoformans) and AD (hybrids of
serotypes A and D which have antigens of the polysaccharide
capsule related to those of the former) [2]. The species
C. gattii contains the serotypes B and C which were previ-
ously known as a variety of C. neoformans (C. neoformans var.
gattii). Currently, the members of these two serotypes,
which are true pathogens, are considered to belong to a
phylogenetically related but distinct species, C. gattii [3].
Loop-mediated isothermal DNA ampliﬁcation (LAMP)
involves the utilization of an isothermal step for DNA ampliﬁ-
cation, thus avoiding the need for sophisticated equipment.
This technique was ﬁrst described by Notomi et al. [4]. It relies
upon an auto-cycling strand displacement DNA synthesis,
using specially designed primer sets and a DNA polymerase
with strand-displacement activity. There is an increasing num-
ber of recent reports on the utilization of LAMP for the detec-
tion and identiﬁcation of organisms of clinical relevance,
including fungi [5,6]. Previous studies have identiﬁed ‘serotype-
associated’ alleles for several genes in the Cryptococcus species
complex, including the virulence, capsule-associated gene
CAP59 [7–9]. We describe a simple LAMP-based method, using
serotype A, D and B/C CAP59 allele-speciﬁc primers, for the
identiﬁcation of strains of the Cryptococcus species complex.
Yeast strains used in this study are listed in Table 1,
including strains of control species. Serotypes were deter-
mined using the Crypto Check kit (Iatron Laboratories,
Tokyo, Japan). For DNA extraction, two loopfuls of culture
grown on agar medium were suspended in lysis buffer to
which the volume equivalent of 200 lL of glass beads was
added, according to Ina´cio et al. [6]. After vortexing for
2 min, the tubes were incubated for 1 h at 65C and vor-
texed again. The suspensions were centrifuged and the su-
pernatants, diluted in sterilized double-distilled water (1:300),
were used directly for DNA ampliﬁcation. Three sets of
LAMP primers were designed according to Notomi et al. [4],
targeting relatively variable sequences within the CAP59 gene:
set ‘A3’ (F3-CN2, AGAAGTCTTTGACTCGGTCG; B3-
CN2, GAAAGGCGCATTCTCGAGC; FIP-A3, GCATTC
TGTCTCCTACTCTGCCAATTGCGTGGACGACTTGCTC;
and BIP-A3, CTGTCCCCCCCTGTTATTCATTATCGTA
GAATACAGGAGCACCCTAG), set ‘D3’ (F3-CN2, B3-CN2,
FIP-D3, CCTACTCTGCCAAATCAACTCGAGCGATATCT
TGCCCTGTGTCG; and BIP-D3, CTGCTTCCGGTTG
TGTTTAGTACTGGCACCCTATGTAGTCATGTGG), and
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TABLE 1. Species and strains used in this study and corresponding serotype and genotype (CAP59-based, LAMP) results
Species Strain Origin Serotype
LAMP
ampliﬁcation
Genotypea‘A3’ ‘D3’ ‘BC’
Cryptococcus
neoformans
CN2 CSF of a HIV 1 infected patient, Egas Moniz’s Hospital, Lisbon,
Portugal (1991)
A ) + ) d
CN4 CSF of a HIV 2 infected patient, Guine Bissau (1992) A + ) ) a
CN23 CSF of a HIV 1 infected patient, Curry Cabral Hospital, Lisbon (1995) A + ) ) a
CN24 CSF of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1995) A + ) ) a
CN27 CSF of a HIV 1 infected patient, Angola (1995) A + ) ) a
CN32 Blood of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1995) A + ) ) a
CN34 CSF of a HIV 1 infected patient, Military Hospital, Lisbon (1995) A + ) ) a
CN43 CSF of a HIV 1 infected patient, Institute of Hygiene and
Tropical Medicine, Lisbon (1996)
A + ) ) a
CN50 CSF of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1996) A + ) ) a
CN54 CSF of a HIV 1 infected patient, Cascais Hospital, Cascais, Portugal (1996) A + ) ) a
CN55 CSF of a HIV 1 infected patient, St Anto´nio Hospital, Oporto, Portugal (1996) A + ) ) a
CN57 CSF of a HIV 1 infected patient, Cascais Hospital, Cascais (1996) A + ) ) a
CN59 CSF of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1996) A + ) ) a
CN65 CSF of a HIV 1 infected patient, St Anto´nio Hospital, Oporto (1996) A + + ) ad
CN70 CSF of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1996) A + + ) ad
CN74 CSF of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1997) A + ) ) a
CN83 CSF of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1997) A + ) ) a
CN87 Bronchial wash of a HIV infected patient, St Anto´nio Hospital, Oporto (1997) A + ) ) a
CN88 CSF of a HIV infected patient, St Anto´nio Hospital, Oporto (1997) A + ) ) a
CN92 CSF of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1997) A + ) ) a
CN100 CSF of a HIV 1 infected patient, S. Jose´ Hospital, Lisbon (1997) A + ) ) a
CN118 CSF of a HIV 1 infected patient, Oncology Portuguese Institute, Lisbon (1998) A + ) ) a
CN123 CSF of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1998) A + ) ) a
CN134 (= PYCC 3530;
CBS 887)
Origin unknown (AFLP genotype 1)b A + ) ) a
CN135 (= PYCC 3533;
CBS 939)
Origin unknown (AFLP ‘hybrid’ genotype 3)b A + + ) ad
CN136 (= PYCC 3534;
CBS 879)
Ulcerated cheek (AFLP genotype 1)b A + ) ) a
WM148 (= CBS 10085) CSF, Australia (molecular type VNI)c A + ) ) a
WM626 (= CBS 10084) CSF, Australia (molecular type VNII)c A + ) ) a
CN48 Skin of a HIV 1 infected patient, Curry Cabral’s Hospital,
Lisbon (1996)
D + + ) ad
CN68 Skin of a HIV 1 infected patient, Egas Moniz Hospital, Lisbon (1996) D ) + ) d
CN77 Skin of a HIV 1 infected patient, Egas Moniz Hospital, Lisbon (1997) D ) + ) d
CN79 CSF of a HIV 1 infected patient, Institut Pasteur, Paris, France (1997) D + + ) ad
CN80 CSF of a HIV 1 infected patient, Institut Pasteur, Paris (1997) D ) + ) d
CN109 CSF of a HIV 1 infected patient, Garcia da Orta Hospital,
Almada, Portugal (1997)
D ) + ) d
CN132 (= PYCC 3528;
CBS 888)
Origin unknown (AFLP genotype 2)b D ) + ) d
CN137T (= PYCC 3957T;
CBS 132T)
Fermenting fruit juice (AFLP ‘hybrid’ genotype 3)b D ) + ) d
WM629 (= CBS 10079) Blood, Australia (molecular type VNIV)c D ) + ) d
CN38 Blood of a HIV 1 infected patient, Santa Maria Hospital,
Lisbon (1996)
AD + ) ) a
CN40 CSF of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1996) AD + ) ) a
CN49 CSF of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1996) AD + + ) ad
CN52 Blood of a HIV 1 infected patient, Santa Maria Hospital, Lisbon (1996) AD + + ) ad
CN73 Skin of a HIV 1 infected patient, Curry Cabral Hospital, Lisbon (1996) AD + + ) ad
CN107 CSF of a HIV 1 infected patient, S. Francisco Xavier Hospital, Lisbon (1997) AD + + ) ad
CN138 (= PYCC 4208;
CBS 6886)
Droppings of pigeon, Denmark (AFLP genotype 2)b AD ) + ) d
WM628 (= CBS 10080) CSF, Australia (‘hybrid’ molecular type VNIII)c AD + + ) ad
Cryptococcus
gattii
CN139 (= PYCC 5025) Eucalyptus, Australia B ) ) + b/c
CN149 (= PYCC 5026) Eucalyptus, Australia B ) ) + b/c
CN151 (= PYCC 5028) Eucalyptus, Australia B ) ) + b/c
WM178 (= CBS 10082) Lung, Australia (molecular type VGII)c B ) ) + b/c
WM161 (= CBS 10081) Eucalyptus debris, USA (molecular type VGIII)c B ) ) + b/c
WM779 (= CBS 10101) Cheata, South Africa (molecular type VGIV)c C ) ) + b/c
Cryptococcus
podzolicus
PYCC 4488T
(= CBS 6819T)
Podzolic soil, Russia ) ) ) ) 0
Cryptococcus
amylolentus
PYCC 4486T
(= CBS 6039T)
Frass of larvae of Enneadesmus forﬁculus (buprestid beetle), in Dombeya
rotundifolia, South Africa
) ) ) ) 0
Filobasidiella
depauperata
PYCC 5605
(= CBS 7841)
Dead spider, Canada ) ) ) ) 0
Tsuchiyaea
wingﬁeldii
PYCC 5373T (= CBS 7118T) Frass of scolytid beetles, in Olea europea subsp. africana, South Africa ) ) ) ) 0
aa—serotype A-associated CAP59 gene allele detected, d—serotype D-associated allele detected, b/c—serotype B- or C-associated allele detected, and 0—no CAP59 gene
alleles detected.
bAccording to Boekhout et al. [2].
cAccording to Meyer et al. [12].
CSF, Cerebrospinal ﬂuid; CBS, Centraalbureau voor Schimelcultures, Utrecht, the Netherlands; T, Type strain; Discrepancies between serotype and genotype are indicated in
bold; All strains are maintained at the Mycology Lab (‘CN’ strains) of the Institute of Hygiene and Tropical Medicine (IHMT/UNL), Lisbon, Portugal, at the Portuguese Yeast
Culture Collection (‘PYCC’ strains), Caparica, Portugal, and at the Molecular Mycology Research Laboratory (‘WM’ strains), University of Sydney at Westmead Hospital,
Westmead, Australia.
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set ‘BC’ (F3-CN, TGGTCCAACTCTGGCTGG; B3-CN,
GCCTTTGTCTGGTCGTTGG; FIP-BC, CCTGGAGATCCC
TCTTGATAACGGTCAATCACGGGGAACGATC; and BIP-
BC, CTTTGCAACCCTCTTCCGGGCATGTGGYATCCCA
AGATGGCG), which are speciﬁc for serotype A, D and B/C
of the Cryptococcus species complex, respectively.
The LAMP reaction mixture contained 1.6 lM of each FIP
and BIP primer, 0.2 lM of each F3 and B3 primer, 1400 lM
of each dNTP, 3.1 lL template DNA solution, 0.8 M betaine
(Sigma-Aldrich, St Louis, USA), 3.75 mM MgCl2, 3.2 U Bst
polymerase (New England Biolabs, Beverly, USA) and the 1X
buffer (provided with the enzyme) for a ﬁnal volume of
10 lL. Template DNA was denatured prior to the ampliﬁca-
tion reaction. The LAMP mixture was incubated at 64C for
130 min in a heater block, followed by a ﬁnal step of 80C
for 5 min to inactivate the enzyme. Amplicons were sepa-
rated electrophoretically in an agarose (1.4%) gel.
LAMP ampliﬁcation results using primer sets ‘A3’, ‘D3’ and
‘BC’ are illustrated in Fig. 1. Ampliﬁcation products were
observed correctly from the serotype A (CN134 and
CN136) and D (CN132 and WM629) reference strains using
the primer sets ‘A3’ and ‘D3’, respectively, producing the
expected ladder-like patterns on the agarose gel. Serotype
AD hybrids presented LAMP ampliﬁcation products, using
both the ‘A3’ and ‘D3’ primer sets (Fig. 1). The primer set
‘BC’ allowed ampliﬁcation of DNA only from serotype B
(WM178) and C (WM779) strains (Fig. 1). The detection limit
of the LAMP assay was c. 100–500 fg/lL (data not shown).
The results of the LAMP ampliﬁcation for a larger num-
ber of strains are presented in Table 1. There was c. 83%
agreement between the results obtained with the Crypto
Check serotyping kit and the CAP59 LAMP-based assay.
Discrepant cases were mainly associated with ambiguous
results of the serotyping kit [10]. Different serotyping
results for the same strain can arise from some unreliability
of the serological methods and/or alterations in the strain
itself that can lead to phenotype changes [3,10,11]. An
interesting case is that of CN137T (CBS132T), the type
strain of C. neoformans. We only detected the serotype D
CAP59 allele in this strain. However, previous work
FIG. 1. Agarose gel electrophoresis of
LAMP products using the primer sets
‘A3’, ‘D3’ and ‘BC’, designed in this
work. Reference strains: CN134 (= CBS
887) and CN136 (= CBS 879), C. neo-
formans var. grubii, serotype A; CN132
(= CBS 888) and WM629 (= CBS
10079), C. neoformans var. neoformans,
serotype D; WM178 (= CBS 10082),
C. gattii, serotype B; WM779 (= CBS
10101), C. gattii, serotype C; CN135
(= CBS 939) and WM628 (= CBS
10080), hybrids between serotype A
and D strains; PYCC 4488T, Cryptococcus
podzolicus; PYCC 4486T, Cryptococcus
amylolentus; PYCC 5605, Filobasidiella
depauperata; and PYCC 5373T,
Tsuchiyaea wingﬁeldii. M, Molecular
Marker GeneRuler DNA Ladder Mix
(Fermentas).
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showed that this strain is diploid, or at least aneuploid, and
probably a hybrid of serotype A and D [2]. As we could
only ﬁnd the serotype D CAP59 allele in this strain, it is
conceivable that it lost the corresponding serotype A
allele. The implication of the loss of CAP59 gene heterozy-
gosity of some hybrids is that, for these strains, our LAMP-
based genotype does not identify its hybrid origin and
erroneously assigns it to either C. neoformans var. grubii
(‘serotype A’) or C. neoformans var. neoformans (‘serotype
D’). This also applies to any genotyping method that relies
on the detection of just one or a few serotype A- and
D-associated gene alleles.
A reliable identiﬁcation of strains of the Cryptococcus
species complex could facilitate timely application of
variety-adapted treatments, improve clinical surveillance
strategies and allow a better description of the epidemio-
logical characteristics of these human-pathogenic yeasts
[10]. The CAP59-based LAMP genotyping described herein
allows the speciﬁc identiﬁcation of and discrimination
between C. neoformans and C. gattii. In addition, the
method allows the identiﬁcation, for most of the strains,
of the C. neoformans variety and/or hybrid origin.
However, the existence of a few serotype A and D aneu-
ploid or diploid hybrids that lost heterozygosity for the CAP59
gene will add some uncertainty to the discrimination of the
correspondent varieties. This uncertainty can be diminished
with the utilization of a mixture of ‘serotype-speciﬁc’ primers
for several genes in a multiplex LAMP reaction, a concept we
will pursue in the future to further optimize our approach.
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